Serum Nestorone® and ethinyl estradiol levels, and ovulation inhibition in women using three different dosage combinations of a Nestorone progestogen-ethinyl estradiol contraceptive vaginal ring on a bleeding-signaled regimen

被引:25
作者
Fraser, IS [1 ]
Weisberg, E
Brache, V
Alvarez, F
Massai, R
Mishell, DR
Apter, D
Gale, J
Tsong, YY
Sivin, I
机构
[1] Univ Sydney, Dept Obstet & Gynaecol, Sydney, NSW 2006, Australia
[2] FPA Hlth, Div Res, Sydney Ctr Reprod Hlth Res, Sydney, NSW 2131, Australia
[3] Profamilia, Santo Domingo, Dominican Rep
[4] Inst Chileno Med Reprod, Depto 101, Santiago, Chile
[5] Univ So Calif, Keck Sch Med, Dept Obstet & Gynecol, Los Angeles, CA 90033 USA
[6] Family Federat Finland, Vaestolitto, Helsinki 00101, Finland
[7] Populat Council, Ctr Biomed Res, New York, NY 10021 USA
关键词
Nestorone; contraceptive vaginal rings; bleeding-signaled regimens; serum Nestorone levels; luteal activity; follicular size;
D O I
10.1016/j.contraception.2004.12.015
中图分类号
R71 [妇产科学];
学科分类号
100211 ;
摘要
Objectives: This trial tested the hypothesis that menstrually signaled use of contraceptive vaginal rings ("rings") releasing low-dose combinations of Nestorone (NES) and ethinyl estradiol (EE) would reliably suppress luteal activity and ovulation, and prevent unintended pregnancy, while controlling the incidence of menstrual bleeding episodes and bleeding days. Methods: Nestorone/ethinyl estradiol rings releasing 50/10, 50/20 and 150/15 mu g/day were studied through 6 months. A ring was to be used continuously, until its removal was signaled by menstrual bleeding. Reinsertion was required 96 h after removal. Serum for NES, EE and progesterone were collected and assayed, and vaginal ultrasound scans were performed in three 5-week periods to examine luteal activity, follicular growth, ovulation and their correlates. In 10 subjects using the 150/15 ring, six samples were drawn in the 24-h period after ring removal to examine serum levels of NES and EE. Results: One hundred sixty subjects at three doses provided blood samples. Median serum concentrations of NES and EE demonstrated dose ratios slightly below the nominal dose ratios expected. Serum NES concentrations declined 19-22% from weeks 3 to 25. Changes in EE levels depended on dose. Nestorone levels fell 81% by 24 h after ring removal and EE levels fell by 50%. Luteal activity was completely suppressed in 94-95% of cycles and in 90% of subjects. Three pregnancies occurred in subjects participating in this serum sampling study. Conclusion: Satisfactory serum levels of NES and EE, and a high level of ovulation suppression were achieved. Irregular ring use, however, permitted pregnancies to occur. (C) 2005 Elsevier Inc. All rights reserved.
引用
收藏
页码:40 / 45
页数:6
相关论文
共 13 条
[1]   EVALUATION OF 4 DIFFERENT CONTRACEPTIVE VAGINAL RINGS - STEROID SERUM LEVELS, LUTEAL ACTIVITY, BLEEDING CONTROL AND LIPID PROFILES [J].
ALVAREZSANCHEZ, F ;
BRACHE, V ;
JACKANICZ, T ;
FAUNDES, A .
CONTRACEPTION, 1992, 46 (04) :387-398
[2]   Ovarian function during use of vaginal rings delivering three different doses of Nestorone® [J].
Brache, V ;
Mishell, DR ;
Lahteenmaki, P ;
Alvarez, F ;
Elomaa, K ;
Jackanicz, T ;
Faundes, A .
CONTRACEPTION, 2001, 63 (05) :257-261
[3]   Progestin-only contraceptive rings [J].
Brache, V ;
Alvarez-Sanchez, F ;
Faundes, A ;
Jackanicz, T ;
Mishell, DR ;
Lähteenmäki, P .
STEROIDS, 2000, 65 (10-11) :687-691
[4]  
JACKANICZ TM, 1984, LONG ACTING CONTRACE, P201
[5]   Nestorone®:: a progestin with a unique pharmacological profile [J].
Kumar, N ;
Koide, SS ;
Tsong, YY ;
Sundaram, K .
STEROIDS, 2000, 65 (10-11) :629-636
[6]  
LAHTEENMAKI P, 1981, CONTRACEPTION, V23, P63
[7]   A CONTRACEPTIVE VAGINAL RING RELEASING ETHINYL ESTRADIOL AND THE PROGESTIN ST-1435 - BLEEDING CONTROL, SERUM STEROID CONCENTRATIONS, SERUM-LIPIDS AND SERUM CHEMISTRY [J].
LAURIKKAROUTTI, M ;
HAUKKAMAA, M ;
HEIKINHEIMO, O .
CONTRACEPTION, 1990, 42 (01) :111-120
[8]   SINGLE-DOSE AND MULTIPLE-DOSE PHARMACOKINETICS OF A LOW-DOSE ORAL-CONTRACEPTIVE IN WOMEN WITH CHRONIC-RENAL-FAILURE UNDERGOING PERITONEAL-DIALYSIS [J].
PRICE, TM ;
DUPUIS, RE ;
CARR, BR ;
STANCZYK, FZ ;
LOBO, RA ;
DROEGEMUELLER, W .
AMERICAN JOURNAL OF OBSTETRICS AND GYNECOLOGY, 1993, 168 (05) :1400-1406
[9]   Nestorone(TM) progestin - The ideal progestin for use in controlled release delivery systems [J].
Robbins, A ;
Bardin, CW .
UTERUS: ENDOMETRIUM AND MYOMETRIUM, 1997, 828 :38-46
[10]   Contraceptive vaginal rings releasing Nestorone® and ethinylestradiol:: a 1-year dose-finding trial? [J].
Sivin, I ;
Mishell, DR ;
Alvarez, F ;
Brache, V ;
Elomaa, K ;
Lähteenmäki, P ;
Massai, R ;
Miranda, P ;
Croxatto, H ;
Dean, C ;
Small, M ;
Nash, H ;
Jackanicz, TM .
CONTRACEPTION, 2005, 71 (02) :122-129